Item Type | Name |
Academic Article
|
Pharmacodynamics of human immunodeficiency virus type 1 protease inhibitors.
|
Academic Article
|
Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
|
Academic Article
|
Pharmacological basis for concentration-controlled therapy with zidovudine, lamivudine, and indinavir.
|
Academic Article
|
The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities.
|
Academic Article
|
The ABC's of pharmacokinetics.
|
Academic Article
|
Pharmacologic perspectives for once-daily antiretroviral therapy.
|
Academic Article
|
Quantitation of zidovudine triphosphate concentrations from human peripheral blood mononuclear cells by anion exchange solid phase extraction and liquid chromatography-tandem mass spectroscopy; an indirect quantitation methodology.
|
Academic Article
|
Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection.
|
Academic Article
|
Comment on: suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir.
|
Academic Article
|
Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study.
|
Academic Article
|
Atazanavir-containing renal calculi in an HIV-infected patient.
|
Academic Article
|
The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.
|
Academic Article
|
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
|
Academic Article
|
PharmGKB summary: zidovudine pathway.
|
Academic Article
|
Clinical pharmacokinetics of antiretroviral drugs in older persons.
|
Academic Article
|
CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related.
|
Academic Article
|
Therapeutic drug monitoring: pharmacologic considerations for antiretroviral drugs.
|
Academic Article
|
Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection.
|
Academic Article
|
Indinavir plasma protein binding in HIV-1-infected adults.
|
Academic Article
|
Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.
|
Academic Article
|
Updated clinical pharmacologic considerations for HIV-1 protease inhibitors.
|
Academic Article
|
Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients.
|
Academic Article
|
Antiretroviral medication adherence and the development of class-specific antiretroviral resistance.
|
Academic Article
|
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
|
Academic Article
|
Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection.
|
Academic Article
|
Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure.
|
Academic Article
|
Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men.
|
Academic Article
|
Effect of HIV-1 infection and sex on the cellular pharmacology of the antiretroviral drugs zidovudine and lamivudine.
|
Concept
|
HIV Infections
|
Academic Article
|
Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP).
|
Academic Article
|
Study product adherence measurement in the iPrEx placebo-controlled trial: concordance with drug detection.
|
Academic Article
|
Tenofovir diphosphate concentrations and prophylactic effect in a macaque model of rectal simian HIV transmission.
|
Academic Article
|
Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study.
|
Academic Article
|
HIV-1 drug resistance in the iPrEx preexposure prophylaxis trial.
|
Academic Article
|
Patterns and correlates of PrEP drug detection among MSM and transgender women in the Global iPrEx Study.
|
Academic Article
|
Dose response for starting and stopping HIV preexposure prophylaxis for men who have sex with men.
|
Academic Article
|
Short communication: Tenofovir diphosphate in dried blood spots as an objective measure of adherence in HIV-infected women.
|
Academic Article
|
Effects of Emtricitabine/Tenofovir on Bone Mineral Density in HIV-Negative Persons in a Randomized, Double-Blind, Placebo-Controlled Trial.
|
Academic Article
|
Relationship Between Genital Drug Concentrations and Cervical Cellular Immune Activation and Reconstitution in HIV-1-Infected Women on a Raltegravir Versus a Boosted Atazanavir Regimen.
|
Academic Article
|
Nondaily preexposure prophylaxis for HIV prevention.
|
Academic Article
|
Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).
|
Academic Article
|
Preexposure Prophylaxis for HIV Infection Integrated With Municipal- and Community-Based Sexual Health Services.
|
Academic Article
|
A phase 1 randomized placebo-controlled safety and pharmacokinetic trial of a tenofovir disoproxil fumarate vaginal ring.
|
Academic Article
|
Application of an intracellular assay for determination of tenofovir-diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots.
|
Academic Article
|
Symptoms, Side Effects and Adherence in the iPrEx Open-Label Extension.
|
Academic Article
|
Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).
|
Academic Article
|
Pharmacologic Considerations for Preexposure Prophylaxis in Transgender Women.
|
Academic Article
|
Novel quantification of tenofovir disoproxil fumarate adherence in human immunodeficiency virus/hepatitis B coinfected patients with incomplete hepatitis B virus viral suppression.
|
Academic Article
|
Analysis of the Endogenous Deoxynucleoside Triphosphate Pool in HIV-Positive and -Negative Individuals Receiving Tenofovir-Emtricitabine.
|
Academic Article
|
Pharmacology supports on-demand PrEP.
|
Academic Article
|
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM.
|
Academic Article
|
Zidovudine and Lamivudine for HIV Infection.
|
Academic Article
|
Emtricitabine-Triphosphate in Dried Blood Spots as a Marker of Recent Dosing.
|
Academic Article
|
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates.
|
Academic Article
|
Suboptimal Adherence to Combination Antiretroviral Therapy Is Associated With Higher Levels of Inflammation Despite HIV Suppression.
|
Academic Article
|
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
|
Academic Article
|
Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
|
Academic Article
|
Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.
|
Academic Article
|
Inflammation and pharmacokinetics: potential implications for HIV-infection.
|
Grant
|
Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis
|
Grant
|
Cellular pharmacology of tenofovir and emtricitabine for HIV prophylaxis
|
Grant
|
Sex and disease dependent nucleoside analog toxicity
|
Academic Article
|
High pre-exposure prophylaxis uptake and early adherence among men who have sex with men and transgender women at risk for HIV Infection: the PrEP Brasil demonstration project.
|
Academic Article
|
Brief Report: Recovery of Bone Mineral Density After Discontinuation of Tenofovir-Based HIV Pre-exposure Prophylaxis.
|
Academic Article
|
Hair levels of preexposure prophylaxis drugs measure adherence and are associated with renal decline among men/transwomen.
|
Academic Article
|
Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
|
Academic Article
|
Plasma Tenofovir Levels to Support Adherence to TDF/FTC Preexposure Prophylaxis for HIV Prevention in MSM in Los Angeles, California.
|
Academic Article
|
Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report.
|
Academic Article
|
Daily and non-daily pre-exposure prophylaxis in African women (HPTN 067/ADAPT Cape Town Trial): a randomised, open-label, phase 2 trial.
|
Academic Article
|
Changes in Kidney Function Associated With Daily Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Preexposure Prophylaxis Use in the United States Demonstration Project.
|
Academic Article
|
Comparison of Measures of Adherence to Human Immunodeficiency Virus Preexposure Prophylaxis Among Adolescent and Young Men Who Have Sex With Men in the United States.
|
Academic Article
|
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots following Directly Observed Therapy.
|
Academic Article
|
Newly Acquired Infection With Multidrug-Resistant HIV-1 in a Patient Adherent to Preexposure Prophylaxis.
|
Academic Article
|
Brief Report: Adherence Biomarker Measurements in Older and Younger HIV-Infected Adults Receiving Tenofovir-Based Therapy.
|
Academic Article
|
Metabolic Effects of Preexposure Prophylaxis With Coformulated Tenofovir Disoproxil Fumarate and Emtricitabine.
|
Academic Article
|
Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.
|
Academic Article
|
Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
|
Academic Article
|
Effects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarate.
|
Academic Article
|
Tenofovir and tenofovir-diphosphate concentrations during pregnancy among HIV-uninfected women using oral preexposure prophylaxis.
|
Academic Article
|
Short Communication: Bioequivalence of Tenofovir and Emtricitabine After Coencapsulation with the Proteus Ingestible Sensor.
|
Academic Article
|
Cryopreservation of human mucosal tissues.
|
Academic Article
|
Transcutaneously refillable nanofluidic implant achieves sustained level of tenofovir diphosphate for HIV pre-exposure prophylaxis.
|
Academic Article
|
Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing.
|
Academic Article
|
Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
|
Academic Article
|
Pharmacologic-Based Methods of Adherence Assessment in HIV Prevention.
|
Academic Article
|
Similar tenofovir hair concentrations in men and women after directly observed dosing of tenofovir disoproxil fumarate/emtricitabine: implications for preexposure prophylaxis adherence monitoring.
|
Academic Article
|
Randomized Controlled Trial of a Mobile Health Intervention to Promote Retention and Adherence to Preexposure Prophylaxis Among Young People at Risk for Human Immunodeficiency Virus: The EPIC Study.
|
Academic Article
|
Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
|
Academic Article
|
Substance Use and Adherence to HIV Preexposure Prophylaxis for Men Who Have Sex with Men1.
|
Academic Article
|
The pharmacokinetics, pharmacodynamics, and mucosal responses to maraviroc-containing pre-exposure prophylaxis regimens in MSM.
|
Academic Article
|
Self-initiated continuation of and adherence to HIV pre-exposure prophylaxis (PrEP) after PrEP demonstration project roll-off in men who have sex with men: associations with risky decision making, impulsivity/disinhibition, and sensation seeking.
|
Academic Article
|
Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy.
|
Academic Article
|
Engagement in Mental Health Care is Associated with Higher Cumulative Drug Exposure and Adherence to Antiretroviral Therapy.
|
Academic Article
|
Predictors of Long-Term HIV Pre-exposure Prophylaxis Adherence After Study Participation in Men Who Have Sex With Men.
|
Academic Article
|
Effective use of pre-exposure prophylaxis (PrEP) Among stimulant users with multiple condomless sex partners: a longitudinal study of men who have sex with men in Los Angeles.
|
Academic Article
|
Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.
|
Academic Article
|
Increased tenofovir monoester concentrations in patients receiving tenofovir disoproxil fumarate with ledipasvir/sofosbuvir.
|
Academic Article
|
Pharmacokinetics of tenofovir monoester and association with intracellular tenofovir diphosphate following single-dose tenofovir disoproxil fumarate.
|
Academic Article
|
Brief Report: Short-Term Adherence Marker to PrEP Predicts Future Nonretention in a Large PrEP Demo Project: Implications for Point-of-Care Adherence Testing.
|
Academic Article
|
Impact of Estimated Pre-Exposure Prophylaxis (PrEP) Adherence Patterns on Bone Mineral Density in a Large PrEP Demonstration Project.
|
Academic Article
|
Changes in Bone Mass After Discontinuation of Preexposure Prophylaxis With Tenofovir Disoproxil Fumarate/Emtricitabine in Young Men Who Have Sex With Men: Extension Phase Results of Adolescent Trials Network Protocols 110 and 113.
|
Academic Article
|
Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm.
|
Academic Article
|
Short Communication: Cascade of Antiretroviral Therapy Adherence in Virologically Suppressed Persons Living with HIV.
|
Academic Article
|
Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
|
Academic Article
|
Performance of HIV pre-exposure prophylaxis indirect adherence measures among men who have sex with men and transgender women: Results from the PrEP Brasil Study.
|
Academic Article
|
Moderately High Tenofovir Diphosphate in Dried Blood Spots Indicates Drug Resistance in Viremic Persons Living with HIV.
|
Academic Article
|
Frequency and Predictors of Tenofovir-diphosphate Detection Among Young Kenyan Women in a Real-world Pre-exposure Prophylaxis Implementation Program.
|
Academic Article
|
Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
|
Academic Article
|
Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV.
|
Academic Article
|
Pharmacology and drug interactions with HIV PrEP in transgender persons receiving gender affirming hormone therapy.
|
Academic Article
|
Approaches to Objectively Measure Antiretroviral Medication Adherence and Drive Adherence Interventions.
|
Academic Article
|
Intracellular Tenofovir-Diphosphate and Emtricitabine-Triphosphate in Dried Blood Spots Following Tenofovir Alafenamide: The TAF-DBS Study.
|
Academic Article
|
HIV Pre-Exposure Prophylaxis for Conception Among HIV Serodiscordant Couples in the United States: A Cohort Study.
|
Academic Article
|
Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
|
Academic Article
|
Use of Drug-level Testing and Single-genome Sequencing to Unravel a Case of Human Immunodeficiency Virus Seroconversion on Pre-exposure Prophylaxis.
|
Academic Article
|
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
|
Academic Article
|
Pharmacokinetics and renal safety of tenofovir alafenamide with boosted protease inhibitors and ledipasvir/sofosbuvir.
|
Academic Article
|
Sex Hormone Therapy and Tenofovir Diphosphate Concentration in Dried Blood Spots: Primary Results of the Interactions Between Antiretrovirals And Transgender Hormones Study.
|
Academic Article
|
Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment.
|
Academic Article
|
Lower Cumulative Antiretroviral Exposure in People Living With HIV and Diabetes Mellitus.
|
Academic Article
|
Individualized Adherence Benchmarks for HIV Pre-Exposure Prophylaxis.
|
Academic Article
|
Tenofovir Diphosphate Concentrations in Dried Blood Spots From Pregnant and Postpartum Adolescent and Young Women Receiving Daily Observed Pre-exposure Prophylaxis in Sub-Saharan Africa.
|
Academic Article
|
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal Antibody.
|
Academic Article
|
HIV Prevention and Treatment Cascades Among Female Sex Workers in Benin, West Africa.
|
Academic Article
|
Effect of SMS reminders on PrEP adherence in young Kenyan women (MPYA study): a randomised controlled trial.
|
Academic Article
|
Higher medication complexity in persons with HIV is associated with lower tenofovir diphosphate in dried blood spots.
|
Academic Article
|
Short Communication: A Descriptive Analysis of Dried Blood Spot Adherence Testing Among Ugandans with HIV Presenting with Cryptococcal Meningitis.
|
Academic Article
|
Higher colorectal tissue HIV infectivity in cisgender women compared with MSM before and during oral preexposure prophylaxis.
|
Academic Article
|
Results from a Pre-exposure Prophylaxis Demonstration Project for At-risk Cisgender Women in the United States.
|
Academic Article
|
Letter to the Editor: Revisiting the Pharmacological Forgiveness of HIV Pre-Exposure Prophylaxis.
|
Academic Article
|
Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
|
Academic Article
|
A comparison of covariate selection techniques applied to pre-exposure prophylaxis (PrEP) drug concentration data in men and transgender women at risk for HIV.
|
Academic Article
|
Improving adherence to daily preexposure prophylaxis among MSM in Amsterdam by providing feedback via a mobile application.
|
Academic Article
|
Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
|
Academic Article
|
Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence.
|
Academic Article
|
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
|
Academic Article
|
Assessing longitudinal patterns of depressive symptoms and the influence of symptom trajectories on HIV pre-exposure prophylaxis adherence among adolescent girls in the HPTN 082 randomized controlled trial.
|
Academic Article
|
The Magnetic Couples Study: protocol for a mixed methods prospective cohort study of HIV-serodifferent heterosexual couples' perspectives and use of pre-exposure prophylaxis (PrEP).
|
Academic Article
|
Tenofovir-diphosphate in peripheral blood mononuclear cells during low, medium and high adherence to emtricitabine/ tenofovir alafenamide vs. emtricitabine/ tenofovir disoproxil fumarate.
|
Academic Article
|
Estimated pill intake with on-demand PrEP with oral TDF/FTC using TFV-DP concentration in dried blood spots in the ANRS IPERGAY trial.
|
Academic Article
|
Tenofovir Diphosphate in Dried Blood Spots in Pregnant and Postpartum Women With HIV in Kenya: A Novel Approach to Measuring Peripartum Adherence.
|
Academic Article
|
Tenofovir diphosphate levels in dried blood spots are associated with virologic failure and resistance to first-line therapy in South Africa: a case-control cohort study.
|
Academic Article
|
Understanding Pre-Exposure Prophylaxis Adherence in Young Women in Kenya.
|
Academic Article
|
Tenofovir diphosphate in dried blood spots predicts future viremia in persons with HIV taking antiretroviral therapy in South Africa.
|
Academic Article
|
Predictors of 007 triphosphate concentrations in dried blood spots in persons with hepatitis C and active drug or alcohol use.
|
Academic Article
|
Miniature mass spectrometer-based point-of-care assay for cabotegravir and rilpivirine in whole blood.
|
Academic Article
|
Genital Inflammation Is Not Associated With Decreased Vaginal Tenofovir Concentrations in Women Taking Oral PrEP.
|
Academic Article
|
Infection with antiretroviral-susceptible HIV in an individual adherent to pre-exposure prophylaxis: strategies for treatment initiation.
|
Academic Article
|
Adherence to Pre-Exposure Prophylaxis for HIV Prevention in a Clinical Setting.
|
Academic Article
|
Randomized Controlled Trial of Daily Text Messages to Support Adherence to Preexposure Prophylaxis in Individuals at Risk for Human Immunodeficiency Virus: The TAPIR Study.
|
Academic Article
|
Low PrEP adherence despite high retention among transgender women in Brazil: the PrEParadas study.
|
Academic Article
|
Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women.
|
Academic Article
|
A Mixed-Methods Study Examining Adherence to and Acceptability of Intravaginal Rings for HIV Prevention: Behavioral Results of MTN-027.
|
Academic Article
|
Utility of Different Adherence Measures for PrEP: Patterns and Incremental Value.
|
Academic Article
|
Risk compensation in HIV PrEP adherence among Black men who have sex with men in HPTN 073 study.
|
Academic Article
|
Self-reported Recent PrEP Dosing and Drug Detection in an Open Label PrEP Study.
|
Academic Article
|
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
|
Academic Article
|
Prospective study of topical testosterone gel (AndroGel) versus intramuscular testosterone in testosterone-deficient HIV-infected men.
|
Academic Article
|
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
|
Academic Article
|
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
|
Academic Article
|
Characterizing HIV-Preventive, Plasma Tenofovir Concentrations-A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials.
|
Academic Article
|
Intimate partner violence and oral HIV pre-exposure prophylaxis adherence among young African women.
|
Academic Article
|
Cumulative tenofovir diphosphate exposure in persons with HIV taking single- vs. multiple-tablet regimens.
|
Academic Article
|
PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project.
|
Academic Article
|
Gender-Affirming Hormone Pharmacokinetics Among Adolescent and Young Adult Transgender Persons Receiving Daily Emtricitabine/Tenofovir Disoproxil Fumarate.
|
Academic Article
|
Impact of feminizing hormone therapy on tenofovir and emtricitabine plasma pharmacokinetics: a nested drug-drug interaction study in a cohort of Brazilian transgender women using HIV pre-exposure prophylaxis.
|
Academic Article
|
Pharmacokinetics of Emtricitabine/Tenofovir Disoproxil Fumarate Among Transgender Adolescents and Young Adults Without HIV Receiving Gender Affirming Hormones.
|
Academic Article
|
Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
|
Academic Article
|
Randomized Controlled Trial of Automated Directly Observed Therapy for Measurement and Support of PrEP Adherence Among Young Men Who have Sex with Men.
|
Academic Article
|
Long-acting injectable Cabotegravir: How drug concentrations could help guide patient management.
|
Academic Article
|
Randomized Trial of Individualized Texting for Adherence Building (iTAB) Plus Motivational Interviewing for PrEP Adherence in Transgender Individuals: The iM-PrEPT Study.
|
Academic Article
|
Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled Analysis.
|
Academic Article
|
Demographic and Clinical Characteristics of Persons with HIV with Viral Load:Adherence Mismatch Who Are at Risk of Future Viremia.
|
Academic Article
|
Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
|
Academic Article
|
High PrEP uptake and objective longitudinal adherence among HIV-exposed women with personal or partner plans for pregnancy in rural Uganda: A cohort study.
|
Academic Article
|
Development of a tool to assess HIV prevention readiness of adolescent girls and young women in HPTN 082 study.
|
Academic Article
|
Comparing Predictive Ability of Two Objective Adherence Measures in a Community-Based Cohort on Antiretroviral Therapy in South Africa: Tenofovir Diphosphate Concentrations and Electronic Adherence Monitors.
|
Academic Article
|
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
|
Academic Article
|
Acceptability and Feasibility of Providing Adherence Feedback Based on Tenofovir Diphosphate in Dried Blood Spots: Results from a Pilot Study Among Patients and Providers in Cape Town, South Africa.
|
Academic Article
|
Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
|
Academic Article
|
Trust in the provider and accurate self-reported PrEP adherence among adolescent girls and young women in South Africa and Zimbabwe: HPTN 082 study.
|
Academic Article
|
A phase I study to assess safety, pharmacokinetics, and pharmacodynamics of a vaginal insert containing tenofovir alafenamide and elvitegravir.
|
Academic Article
|
Measuring ART Adherence Among Young Adults with Perinatally Acquired HIV: Comparison Between Self-report, Telephone-Based Pill Count, and Objective Pharmacologic Measures.
|
Academic Article
|
Determinants of adherence to daily PrEP measured as intracellular tenofovir diphosphate concentrations over 24 months of follow-up among men who have sex with men.
|
Academic Article
|
Performance of Multiple Adherence Measures for pre-exposure Prophylaxis (PrEP) Among Young Women in Kenya.
|
Academic Article
|
Long-acting refillable nanofluidic implant confers protection against SHIV infection in nonhuman primates.
|
Academic Article
|
HIV pre-exposure prophylaxis initiation, persistence, and adherence during pregnancy through the postpartum period.
|
Academic Article
|
Estradiol and Spironolactone Plasma Pharmacokinetics Among Brazilian Transgender Women Using HIV Pre-Exposure Prophylaxis: Analysis of Potential Interactions.
|
Academic Article
|
Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa.
|
Academic Article
|
Efficacy estimates of oral pre-exposure prophylaxis for HIV prevention in cisgender women with partial adherence.
|
Academic Article
|
Association of tenofovir diphosphate and lamivudine triphosphate concentrations with HIV and hepatitis B virus viral suppression.
|
Academic Article
|
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial.
|
Academic Article
|
Viral and host mediators of non-suppressible HIV-1 viremia.
|
Academic Article
|
Adults on pre-exposure prophylaxis (tenofovir-emtricitabine) have faster clearance of anti-HIV monoclonal antibody VRC01.
|
Academic Article
|
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
|
Academic Article
|
Antiviral potency of long-acting islatravir subdermal implant in SHIV-infected macaques.
|